We believe PharmaCom BioVet is a prime example of an excellent growth opportunity. We look forward to providing the necessary financial and strategic guidance to help the company achieve its full potential.
Raleigh, NC (PRWEB) December 16, 2008
PharmaCom BioVet, Inc. (PINKSHEETS: PHMB). PharmaCom BioVet, Inc. is pleased to announce the Company has retained the services of boutique merchant bank; Shulman & Asc., to assist the Company to execute its aggressive business model, raise corporate awareness, raise capital and manage the immediate future growth of the Company.
PharmaCom BioVet, Inc. President and CEO, Gary Berthold stated: "We are pleased to welcome the unique and seasoned expertise that Shulman & Associates, LLC brings to PharmaCom BioVet, Inc. This relationship will enable PharmaCom to obtain world wide exposure and become a recognized force in the marketplace. The financial wisdom and vision of Shulman & Associates will assure that we move forward with aggressive strategies that will position our company for optimum growth and success."
Manny Shulman, Managing Partner of Shulman & Associates, LLC commented, "We believe PharmaCom BioVet is a prime example of an excellent growth opportunity. We look forward to providing the necessary financial and strategic guidance to help the company achieve its full potential." Shulman and Associates LLC, based in Boca Raton, Florida is a merchant banking firm specializing in mergers and acquisitions, investment banking services and corporate finance.
PharmaCom BioVet, Inc. is the inspiration of Gary and Sharon Berthold of Raleigh, NC. Avid Siberian Husky breeders and life-long dog lovers, the Berthold's were driven to establish the company following the loss of two of their most precious Siberian Huskies to cancer. While researching medical remedies, they discovered a growing nationwide demand for canine cancer care along with an astonishing lack of effective treatment options. To address these realities, they formed PharmaCom BioVet, Inc. to establish canine cancer treatment centers around the country. These facilities will link the brightest veterinary leaders with the latest oncology technologies to offer the most advanced cancer treatment programs available.
About PharmaCom BioVet, Inc.:
PharmaCom BioVet, Inc. is dedicated to advancing the veterinary care industry for companion animals by establishing state-of-the-art treatment centers for lymphoma and other forms of cancer throughout the country. The purpose of these centers is to help prolong the quality of life for companion animals with cancer and pursue the potential for complete cure. These centers will also operate under the philosophy of providing a compassionate care environment for both companion animal patients and their owners. For more information, please visit our website http://www.PharmaComBioVet.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that are subject to risk and uncertainties, including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in PharmaCom BioVet, Inc.'s filings with the Securities and Exchange Commission. These risks could cause PharmaCom BioVet, Inc.'s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, PharmaCom BioVet, Inc.
P.O. Box 16004
Chapel Hill, NC 27516
SOURCE: PharmaCom BioVet, Inc.